Ideaya biosciences, inc. (IDYA)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Cash flows from operating activities
Net loss

-41,975

-34,346

-11,862

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization

1,245

886

391

Net amortization of premiums and discounts on marketable securities

473

808

27

Stock-based compensation

2,168

950

136

Issuance of Series B redeemable convertible preferred stock pursuant to license agreement

-

3,812

-

Change in fair value of redeemable convertible preferred stock liability

-

70

2,426

Landlord contributions for leasehold improvements

-

367

-

Loss on sale of property and equipment

-14

54

-

Gain on sales of marketable securities

8

11

-

Changes in assets and liabilities
Prepaid expenses and other assets

1,963

243

-331

Right-of-use assets

-1,093

-

-

Accounts payable

-195

322

254

Accrued and other liabilities

2,030

1,672

1,015

Deferred rent

-

-97

-36

Lease liabilities

-1,249

-

-

Net cash used in operating activities

-39,313

-27,620

-12,224

Cash flows from investing activities
Purchases of property and equipment, net

1,353

1,708

1,757

Purchases of marketable securities

88,004

133,301

13,470

Maturities of marketable securities

73,528

65,830

6,300

Sales of marketable securities

18,094

6,000

-

Net cash provided by investing activities

2,265

-63,179

-8,927

Cash flows from financing activities
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

105,358

17,264

Proceeds from issuance of common stock in initial public offering, net of issuance costs

50,321

-

-

Proceeds from exercise of common stock options

289

91

226

Payments of deferred offering costs

-

71

-

Net cash provided by (used in) financing activities

50,610

105,378

17,490

Net increase in cash, cash equivalents and restricted cash

13,562

14,579

-3,661

Supplemental disclosure of cash flow information:
Cash paid for income taxes

1

1

-

Cash paid for interest

91

99

19

Supplemental non-cash investing and financing activities:
Leasehold improvements acquired through tenant improvement allowance

-

-

1,637

Unpaid deferred offering costs

-

499

-

Vesting of early exercised options and restricted stock

114

189

120

Purchases of property and equipment in accounts payable and accrued liabilities

-

604

70

Extinguishment of redeemable convertible preferred stock liability

-

3,137

135

Conversion of redeemable convertible preferred stock into common stock

138,391

-

-

Series B Redeemable Convertible Preferred Stock
Issuance of Series B redeemable convertible preferred stock pursuant to license agreement

-

3,812

-